A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company is set to start a phase 2/3 trial this month.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Global phase 2 data in TNBC look similar to earlier results in China.
